Melius Pharma is a Swedish company founded in 2021 focused on the development of new treatments for interstitial lung diseases.
The company’s lead project for chronic cough in idiopathic pulmonary fibrosis is set to enter a Phase IIa clinical proof of concept study. Chronic cough is a serious symptom in idiopathic pulmonary fibrosis that severely affects the quality of life in patients suffering from this disease. Median survival for patients after diagnosis is 3–5 years with current treatments according to the company.
Melius Pharma says its drug candidate is a new chemical entity benefiting from more than 20 years of safety data in man as well as efficacy data from both clinical and preclinical cough studies.
THERAtRAME was founded based on new insights in transfer RNA (tRNA) epitranscriptomics resulting from over a decade of fundamental research at the GIGA Institute (ULiège) and WELBIO. Transfer RNAs mediate …
NEOsphere Biotechnologies is a German biotech startup that has developed a proteomic platform for systematic identification of novel targets for targeted protein degradation. NEOsphere uses cutting-edge mass spectrometry technology to …
Founded in 2021, Epigenic Therapeutics is a Chinese startup developing next generation gene editing therapies for a wide variety of diseases, using modulation of the epigenetic genome. Epigenic Therapeutics’ proprietary …
hC Bioscience is developing Transfer RNA-based therapeutics targeting protein dysfunction. Transfer RNA (tRNA) is a small RNA molecule that plays a key role in protein synthesis. tRNA serves as a …
